|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Net revenue | ||
| Genomic | ||
| Data and Services | ||
| Diagnostics | ||
| Data and applications | ||
| Total net revenue | ||
| Cost and operating expenses | ||
| Cost of revenues | ||
| Genomic | ||
| Data and Services | ||
| Diagnostics | ||
| Data and applications | ||
| Technology research and development | ||
| Research and development | ||
| Selling, general and administrative | ||
| Total cost and operating expenses | ||
| Loss from operations | ||
| Interest income | ||
| Interest expense | ||
| Loss on debt extinguishment | ||
| Other income, net | ||
| Loss before benefit from (provision for) income taxes | ||
| Provision for income taxes | ||
| benefit from (Provision for) income taxes | ||
| losses from equity method investments | ||
| Net Loss | ||
| Foreign currency translation adjustment | ||
| Comprehensive loss | ||
| Accretion of convertible preferred stock to redemption value | ||
| Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares | ||
| Cumulative undeclared dividends on Series C preferred shares | ||
| Net loss attributable to common shareholders, basic | ||
| Net loss attributable to common shareholders, diluted | ||
| Net loss per share attributable to common shareholders, basic | ||
| Net loss per share attributable to common shareholders, diluted | ||
| Weighted-average shares outstanding used to compute net loss per share, basic | ||
| Weighted-average shares outstanding used to compute net loss per share, diluted |
Loading...
